April SAS-B figures: pastilles hit nearly one-third of approvals by Adam Sheldon May 7, 2026May 7, 2026 Approvals through the Special Access Scheme fell below 20,000 in April, as pastilles continued to cement […]
Bioxyne lifts FY26 guidance after margin growth in strong first half by Steve Jones February 26, 2026February 26, 2026
TGA offers first clues to where industry can expect to face regulatory reform by Steve Jones February 23, 2026February 25, 2026
Pastilles surge again as SAS-B data shows strong start to 2026 by Steve Jones February 2, 2026February 3, 2026
SAS-B deep dive: approvals climb 26% in 2025 as flower overtakes oil and pastilles surge by Adam Sheldon January 13, 2026January 14, 2026
Bioxyne enters Central American markets with pastille supply deal by Steve Jones December 12, 2025December 12, 2025
Pastilles climb past oil to become second largest SAS-B dosage form by Steve Jones December 2, 2025December 4, 2025
Pastilles overtake oil among 18-44 age group as SAS-B approvals near 2024 total by Steve Jones October 1, 2025October 1, 2025
